Anti-GLP-1 抗体 [4F3] (ab23472)
Key features and details
- Mouse monoclonal [4F3] to GLP-1
- Suitable for: IHC-P, ELISA
- Reacts with: Human
- Isotype: IgG1
製品の概要
-
製品名
Anti-GLP-1 antibody [4F3]
GLP-1 一次抗体 製品一覧 -
製品の詳細
Mouse monoclonal [4F3] to GLP-1 -
由来種
Mouse -
特異性
Reacts with all forms of GLP1, including precursor and GLP1(9-37) /GLP1(9-36amide) metabolite. ab23472 cross-reacts with Liraglutide. -
アプリケーション
適用あり: IHC-P, ELISAmore details -
種交差性
交差種: Human
交差が予測される動物種: Mammals -
免疫原
Synthetic peptide within Human GLP-1 aa 1 to the C-terminus. The exact immunogen sequence used to generate this antibody is proprietary information. If additional detail on the immunogen is needed to determine the suitability of the antibody for your needs, please contact our Scientific Support team to discuss your requirements.
Database link: P01275 -
エピトープ
Mid molecular epitope of GLP1. -
ポジティブ・コントロール
- IHC-P: Human pancreas tissue
-
特記事項
The Life Science industry has been in the grips of a reproducibility crisis for a number of years. Abcam is leading the way in addressing this with our range of recombinant monoclonal antibodies and knockout edited cell lines for gold-standard validation. Please check that this product meets your needs before purchasing.
If you have any questions, special requirements or concerns, please send us an inquiry and/or contact our Support team ahead of purchase. Recommended alternatives for this product can be found below, along with publications, customer reviews and Q&As
製品の特性
-
製品の状態
Liquid -
保存方法
Shipped at 4°C. Store at +4°C short term (1-2 weeks). Store at -20°C or -80°C. Avoid freeze / thaw cycle. -
バッファー
pH: 7.40
Preservative: 0.097% Sodium azide
Constituents: 0.0268% PBS, 2.9% Sodium chloride -
Concentration information loading...
-
精製度
Protein G purified -
ポリ/モノ
モノクローナル -
クローン名
4F3 -
ミエローマ
x63-Ag8.653 -
アイソタイプ
IgG1 -
軽鎖の種類
kappa -
研究分野
関連製品
-
Compatible Secondaries
-
Isotype control
-
Recombinant Protein
-
sELISA pair antibody
アプリケーション
The Abpromise guarantee
Abpromise保証は、 次のテスト済みアプリケーションにおけるab23472の使用に適用されます
アプリケーションノートには、推奨の開始希釈率がありますが、適切な希釈率につきましてはご検討ください。
アプリケーション | Abreviews | 特記事項 |
---|---|---|
IHC-P |
1/1000.
|
|
ELISA |
Use at an assay dependent concentration. PubMed: 29953011
|
特記事項 |
---|
IHC-P
1/1000. |
ELISA
Use at an assay dependent concentration. PubMed: 29953011 |
ターゲット情報
-
機能
Glucagon plays a key role in glucose metabolism and homeostasis. Regulates blood glucose by increasing gluconeogenesis and decreasing glycolysis. A counterregulatory hormone of insulin, raises plasma glucose levels in response to insulin-induced hypoglycemia. Plays an important role in initiating and maintaining hyperglycemic conditions in diabetes.
GLP-1 is a potent stimulator of glucose-dependent insulin release. Play important roles on gastric motility and the suppression of plasma glucagon levels. May be involved in the suppression of satiety and stimulation of glucose disposal in peripheral tissues, independent of the actions of insulin. Have growth-promoting activities on intestinal epithelium. May also regulate the hypothalamic pituitary axis (HPA) via effects on LH, TSH, CRH, oxytocin, and vasopressin secretion. Increases islet mass through stimulation of islet neogenesis and pancreatic beta cell proliferaton. Inhibits beta cell apoptosis.
GLP-2 stimulates intestinal growth and up-regulates villus height in the small intestine, concomitant with increased crypt cell proliferation and decreased enterocyte apoptosis. The gastrointestinal tract, from the stomach to the colon is the principal target for GLP-2 action. Plays a key role in nutrient homeostasis, enhancing nutrient assimilation through enhanced gastrointestinal function, as well as increasing nutrient disposal. Stimulates intestinal glucose transport and decreases mucosal permeability.
Oxyntomodulin significantly reduces food intake. Inhibits gastric emptying in humans. Suppression of gastric emptying may lead to increased gastric distension, which may contribute to satiety by causing a sensation of fullness.
Glicentin may modulate gastric acid secretion and the gastro-pyloro-duodenal activity. May play an important role in intestinal mucosal growth in the early period of life. -
組織特異性
Glucagon is secreted in the A cells of the islets of Langerhans. GLP-1, GLP-2, oxyntomodulin and glicentin are secreted from enteroendocrine cells throughout the gastrointestinal tract. GLP1 and GLP2 are also secreted in selected neurons in the brain. -
配列類似性
Belongs to the glucagon family. -
翻訳後修飾
Proglucagon is post-translationally processed in a tissue-specific manner in pancreatic A cells and intestinal L cells. In pancreatic A cells, the major bioactive hormone is glucagon cleaved by PCSK2/PC2. In the intestinal L cells PCSK1/PC1 liberates GLP-1, GLP-2, glicentin and oxyntomodulin. GLP-1 is further N-terminally truncated by post-translational processing in the intestinal L cells resulting in GLP-1(7-37) GLP-1-(7-36)amide. The C-terminal amidation is neither important for the metabolism of GLP-1 nor for its effects on the endocrine pancreas. -
細胞内局在
Secreted. - Information by UniProt
-
参照データベース
- Entrez Gene: 2641 Human
- Omim: 138030 Human
- SwissProt: P01275 Human
- Unigene: 516494 Human
-
別名
- GCG antibody
- Glicentin related polypeptide antibody
- glicentin-related polypeptide antibody
see all
画像
-
ab23472 (1µg/ml) staining GLP-1 in human pancreas, using an automated system (DAKO Autostainer Plus). Using this protocol there is strong cytoplasmic staining.
Sections were rehydrated and antigen retrieved with the Dako 3 in 1 AR buffer citrate pH6.1 in a DAKO PT link. Slides were peroxidase blocked in 3% H2O2 in methanol for 10 mins. They were then blocked with Dako Protein block for 10 minutes (containing casein 0.25% in PBS) then incubated with primary antibody for 20 min and detected with Dako envision flex amplification kit for 30 minutes. Colorimetric detection was completed with Diaminobenzidine for 5 minutes. Slides were counterstained with Haematoxylin and coverslipped under DePeX. Please note that, for manual staining, optimization of primary antibody concentration and incubation time is recommended. Signal amplification may be required.
プロトコール
データシートおよび資料
-
SDS download
-
Datasheet download
参考文献 (10)
ab23472 は 10 報の論文で使用されています。
- Odongo K et al. Development of sandwich ELISAs for detecting glucagon-like peptide-1 secretion from intestinal L-cells and their application in STC-1 cells and mice. J Clin Biochem Nutr 72:28-38 (2023). PubMed: 36777078
- Fujiwara Y et al. Carbonic anhydrase 8 (CAR8) negatively regulates GLP-1 secretion from enteroendocrine cells in response to long-chain fatty acids. Am J Physiol Gastrointest Liver Physiol 320:G617-G626 (2021). PubMed: 33533304
- Lang S et al. Glucagon receptor antagonism promotes the production of gut proglucagon-derived peptides in diabetic mice. Peptides 131:170349 (2020). PubMed: 32561493
- Zhang X et al. Fructose malabsorption induces cholecystokinin expression in the ileum and cecum by changing microbiota composition and metabolism. FASEB J 33:7126-7142 (2019). PubMed: 30939042
- Weng S et al. Prevalence and factors associated with nonalcoholic fatty pancreas disease and its severity in China. Medicine (Baltimore) 97:e11293 (2018). PubMed: 29953011
- Xu F et al. Modified human glucagon-like peptide-1 (GLP-1) produced in E. coli has a long-acting therapeutic effect in type 2 diabetic mice. PLoS One 12:e0181939 (2017). PubMed: 28750064
- Okita N et al. Modified Western blotting for insulin and other diabetes-associated peptide hormones. Sci Rep 7:6949 (2017). PubMed: 28761041
- Jiang S et al. AMPK-dependent regulation of GLP1 expression in L-like cells. J Mol Endocrinol 57:151-60 (2016). PubMed: 27493247
- Marchetti P et al. A local glucagon-like peptide 1 (GLP-1) system in human pancreatic islets. Diabetologia 55:3262-72 (2012). PubMed: 22965295
- Fishbein TM et al. Rejection reversibly alters enteroendocrine cell renewal in the transplanted small intestine. Am J Transplant 9:1620-8 (2009). WB ; Human . PubMed: 19519821